Since announcing our intention to combine Actavis and Allergan last November, we have clearly communicated that part of combining our companies will be capturing cost savings, particularly in overlapping areas within the two organizations. We expect to achieve approximately $1.8 billion in operating and financial synergies within one year following the close. This will be challenging, because as we are all aware, part of this savings will come from a reduction in our global workforce.